Amantadine effectiveness in multiple system atrophy and progressive supranuclear palsy

A. H. Rajput, R. J. Uitti, M. E. Fenton, D. George

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) each respond poorly to most anti-parkinsonian drugs. We assessed PSP and MSA cases seen between 1970 and 1996 for response to amantadine (Amd) 100 mg twice daily. Of 13 MSA cases (six females, seven males), eight (61.5%) improved, four (30.8%) did not benefit and one had insufficient documentation. Adverse effects were observed in three (23.1%) cases. Of 14 PSP (three females, 11 males), six (42.9%) had some improvement, five (35.7%) had no benefit, and three (21.4%) had inadequate documentation. Adverse effects were noted in three (28.6%) cases. Improvement is likely related to NMDA antagonist properties of Amd. We recommend consideration of Amd in the management of both PSP and MSA.

Original languageEnglish (US)
Pages (from-to)211-214
Number of pages4
JournalParkinsonism and Related Disorders
Issue number4
StatePublished - Dec 1998


  • Amantadine
  • Multiple system atrophy
  • Progressive supranuclear palsy

ASJC Scopus subject areas

  • Neurology
  • Geriatrics and Gerontology
  • Clinical Neurology


Dive into the research topics of 'Amantadine effectiveness in multiple system atrophy and progressive supranuclear palsy'. Together they form a unique fingerprint.

Cite this